Form 4: Agenus CEO Garo Armen Opts for Stock-Based Salary, Acquires 2,317 Shares

Agenus Inc.'s Chairman and CEO, Garo H. Armen, has elected to receive his salary in common stock, acquiring 2,317 shares at $7.06 per share, effective July 11, 2025.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 2,317 shares of Agenus Common Stock.
• The transaction occurred on July 11, 2025, with shares priced at $7.06 each, which was the closing price on that date.
• This acquisition represents the net amount of Dr. Armen's salary for the pay period ending July 11, 2025, paid in stock instead of cash at his request and with Compensation Committee approval.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested upon issuance.
• Following this transaction, Dr. Armen directly beneficially owns 261,159 shares of Common Stock.
• Indirect beneficial ownership includes 31,298 shares held in Dr. Armen's IRA accounts.
• Additionally, Dr. Armen indirectly beneficially owns 28,950 shares through the Garo Armen 2020 2 Year AG GRAT (23,950 shares) and Pixie Partners (5,000 shares), though he disclaims pecuniary interest in a portion of Pixie Partners' shares.

Sentiment

Score: 7

Explanation: The decision by the CEO to take salary in stock is generally viewed positively as it aligns management's interests with shareholders and signals confidence in the company's future. While the transaction itself is small in scale relative to total holdings, the underlying principle is favorable.

Positives

• The CEO's decision to receive salary in stock demonstrates a strong alignment of management's interests with those of shareholders, indicating confidence in the company's future performance.
• The shares acquired are fully vested on the date of issuance, providing immediate ownership and reducing future vesting complexities.

Future Outlook

No specific forward-looking statements or guidance are provided beyond the future transaction date of July 11, 2025.

Management Comments

• Garo H. Armen's salary is being paid in stock, in lieu of cash, at his request and with the approval of the Agenus Inc. Compensation Committee.

Industry Context

This filing is a standard disclosure of an insider transaction, common across all industries, particularly in biotechnology where executive compensation often includes equity components to align with long-term company performance and innovation cycles.

Comparison to Industry Standards

• The practice of executives opting for stock-based compensation in lieu of cash salary is a common strategy in the biotechnology and pharmaceutical sectors, aligning executive incentives with shareholder value creation.
• This aligns with compensation structures seen in companies like Moderna, BioNTech, or Regeneron, where significant portions of executive pay are often equity-based, reflecting confidence in pipeline development and future market potential.

Related Party Transactions

• Shares are held in Dr. Armen's IRA accounts (31,298 shares).
• Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT, which holds 23,950 shares.
• Dr. Armen is a general partner in Pixie Partners, which owns 5,000 shares, though he disclaims beneficial ownership to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The CEO's choice to receive salary in stock can be interpreted as a positive signal of management's belief in the company's long-term value, potentially boosting investor confidence.
• Employees: The compensation structure for the CEO may set a precedent or reflect a broader company philosophy regarding equity-based incentives, potentially influencing employee compensation strategies.

Key Dates

Recommendation

Keywords

Agenus Inc., AGEN, Garo H. Armen, SEC Form 4, Insider Trading, Stock-based compensation, Equity Incentive Plan, CEO compensation, Share acquisition, Common Stock